Class Action Filed Against Helen of Troy Underscores Legal Risk Amid Turnaround Efforts

What happened

Helen of Troy (HELE) faces a new class action lawsuit from Bronstein, Gewirtz & Grossman LLC on behalf of investors who purchased shares between April 2024 and October 2025, a period marked by tariff disruptions, $806.7 million in impairment charges, and repeated guidance cuts. The suit alleges violations of federal securities laws, potentially adding legal costs and reputational pressure to a company already battling to restore operational stability and lender confidence. Despite these headwinds, HELE's core investment debate remains centered on its ability to execute tariff mitigation—reducing China sourcing exposure and eliminating stop-shipments—while maintaining covenant compliance. The lawsuit does not directly alter the fundamental thesis, but it raises the stakes by diverting management attention and potentially impacting already constrained liquidity. Until clear evidence emerges that tariff-related disruptions are subsiding and credit metrics improve, the stock warrants a cautious stance.

Implication

Over the next six to twelve months, the lawsuit outcome will matter only insofar as it affects financial flexibility; a large settlement or judgment could strain HELE's tight liquidity. The primary drivers remain the cessation of stop-shipments, progress on dual-sourcing, and EBITDA recovery ahead of covenant step-downs. If the company delivers on its tariff mitigation targets, the lawsuit overhang could fade as a concern. Conversely, if operational challenges persist, the legal liability adds another layer of risk to an already fragile turnaround. Investors should monitor legal developments but focus on the company’s upcoming quarterly reports for proof of execution.

Thesis delta

The class action introduces an additional risk factor—litigation—that slightly increases downside uncertainty but does not change the base-case valuation or the WAIT rating. The investment thesis still depends on tariff mitigation execution and covenant management; the lawsuit’s financial impact remains uncertain and likely manageable if operations stabilize. We maintain the view that entry is more attractive below $15, with re-assessment warranted in 3-6 months.